Immusoft >>

The post First-in-Human Clinical Trial of Autologous Human B Cells Engineered to Express Human Iduronidase in Subjects with MPS I appeared first on Immusoft.

SAN FRANCISCO, May 06, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that Scott McIvor, Chief Development Officer at Immusoft, will present recent clinical data in a

SAN FRANCISCO, May 6, 2025 (Globe Newswire) - Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that Scott McIvor, Chief Development Officer at Immusoft, will present recent clinical data in a p

The post Advancing Pediatric CGT Clinical Trials: Scientific, Ethical, Regulatory & Practical Considerations appeared first on Immusoft.

The post Translational data from the first-in-human clinical trial of autologous human B cells engineered to express human iduronidase in subjects with MPS I appeared first on Immusoft.

Prospectively designed for scalability and re-dosability, Immusoft's engineered B cells represent the next generation of advanced therapeutics

Prospectively designed for scalability and re-dosability, Immusoft's engineered B cells represent the next generation of advanced therapeutics San Francisco, CA., April 8, 2026 - Immusoft of CA, a clinical-stage biotechnology company pioneering engineered

Funding will enable the Company to support expanded development of its lead asset, ISP-001, for the treatment of mucopolysaccharidosis type 1 San Francisco, CA., March 30, 2026 - Immusoft of CA, a clinical-stage biotechnology company pioneering engineered

The post From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era appeared first on Immusoft.

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight.